Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Not for human or veterinary consumption, diagnosis, or treatment
Participants who faced access issues reported a 13.7% weight loss within 12 months and a 14.9% loss within 24 months, on average
As mentioned, the GLP-1 drugs work best alongside lifestyle and diet changes, as well as exercise, so start there
In clinical studies, tirzepatide (Mounjaro) demonstrated greater average weight reduction than semaglutide (Ozempic), though individual response varies
Clinical trials have demonstrated that exendin-4-based therapies reduce HbA1c levels by approximately 9-16 mmol/mol (0.81.5%) when added to existing oral antidiabetic agents
10.1186/1476-4598-12-86 31 ImaiS.ArmstrongC
US$ 23.85
US$ 21.53
US$ 20.16
